Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation – Regeneron

1. Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation  Regeneron
2. FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC  The American Journal of Managed Care® (AJMC®)
3. FDA Approves Libtayo for Cutaneous Squamous Cell Carcinoma Treatment  CUREtoday.com
4. Regeneron stock rises after FDA approves Libtayo for high-risk skin cancer  Investing.com
5. FDA Approves Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma  Oncology Nursing News

Continue Reading